Advances in fibroblast growth factor signaling in growth plate development and disorders

Journal of Molecular Endocrinology

Volumn 53, Issue 1, 2014, Pages

  Xie, Yangli ^a   Zhou, Siru ^a   Chen, Hangang ^a   Du, Xiaolan ^a   Chen, Lin ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Disorder; FGF signaling; Growth plate; Mouse model; Review

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR;

ARTICLE; BONE DEVELOPMENT; BONE DISEASE; BONE DYSPLASIA; ENCHONDRAL OSSIFICATION; GROWTH PLATE; HUMAN; MISSENSE MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; BONE DISEASES, DEVELOPMENTAL; GENETICS; GROWTH, DEVELOPMENT AND AGING; MOUSE; MUTATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BONE DEVELOPMENT; BONE DISEASES, DEVELOPMENTAL; FIBROBLAST GROWTH FACTORS; GROWTH PLATE; HUMANS; MICE; MUTATION; OSTEOGENESIS; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84940286327     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-14-0012     Document Type: Article

References (268)

1. Agochukwu NB, Solomon BD, Gropman AL & Muenke M 2012 Epilepsy in Muenke syndrome: FGFR3-related craniosynostosis. Pediatric Neurology 47355-361. (doi:10.1016/j.pediatrneurol.2012.07.004)
2. Ambrosetti D, Holmes G, Mansukhani A & Basilico C 2008 Fibroblast growth factor signaling uses multiple mechanisms to inhibit Wnt-induced transcription in osteoblasts. Molecular and Cellular Biology 28 4759-4771. (doi:10.1128/MCB.01849-07)
3. Amizuka N, Ozawa H & Sasaki T 2000 The biological action of parathyroid hormone-related peptide (PTHrP) and fibroblast growth factor receptor 3 (FGFR3) on bone and cartilage. Kaibogaku Zasshi. Journal of Anatomy 75415-425.
4. Amizuka N, Davidson D, Liu H, Valverde-Franco G, Chai S, Maeda T, Ozawa H, Hammond V, Ornitz DM, Goltzman D et al. 2004 Signalling by fibroblast growth factor receptor 3 and parathyroid hormone-related peptide coordinate cartilage and bone development. Bone 34 13-25. (doi:10.1016/j.bone.2003.08.009)
5. Aono Y, Yamazaki Y, Yasutake J, Kawata T, Hasegawa H, Urakawa I, Fujita T, Wada M, Yamashita T, Fukumoto S et al. 2009 Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. Journal of Bone and Mineral Research 24 1879-1888. (doi:10.1359/jbmr.090509)
6. Aono Y, Hasegawa H, Yamazaki Y, Shimada T, Fujita T, Yamashita T & Fukumoto S 2011 Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice. Journal of Bone and Mineral Research 26 803-810. (doi:10.1002/jbmr.275)
7. Arnaud-Lopez L, Fragoso R, Mantilla-Capacho J & Barros-Nunez P 2007 Crouzon with acanthosis nigricans. Further delineation of the syndrome. Clinical Genetics 72 405-410. (doi:10.1111/j.1399-0004.2007.00884.x)
8. Bach FC, Rutten KR, Hendriks K, Riemers FM, Cornelissen P, de Bruin A, Arkesteijn GJ, Wubbolts RW, Horton WA, Penning LC et al. 2014 The paracrine feedback loop between vitamin D3 (1,25(OH)2D3) and PTHrP in prehypertrophic chondrocytes. Journal of Cellular Physiology [in press]. (doi:10.1002/jcp.24658)
9. Bai X, Miao D, Li J, Goltzman D & Karaplis AC 2004 Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145 5269-5279. (doi:10.1210/en.2004-0233)
10. Barroso E, Perez-Carrizosa V, Garcia-Recuero I, Glucksman MJ, Wilkie AO, Garcia-Minaur S & Heath KE 2011 Mild isolated craniosynostosis due to a novel FGFR3 mutation, p.Ala334Thr. American Journal of Medical Genetics. Part A 155A 3050-3053. (doi:10.1002/ajmg.a.34199)
11. Bernheim J & Benchetrit S 2011 The potential roles of FGF23 and Klotho in the prognosis of renal and cardiovascular diseases. Nephrology, Dialysis, Transplantation 26 2433-2438. (doi:10.1093/ndt/gfr208)
12. Bonewald LF & Wacker MJ 2013 FGF23 production by osteocytes. Pediatric Nephrology 28 563-568. (doi:10.1007/s00467-012-2309-3)
13. Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF, Lieben L, Mathieu C & Demay M 2008 Vitamin D and human health: lessons from vitamin D receptor null mice. Endocrine Reviews 29 726-776. (doi:10.1210/er.2008-0004)
14. Burdan F, Szumilo J, Korobowicz A, Farooquee R, Patel S, Patel A, Dave A, Szumilo M, Solecki M, Klepacz R et al. 2009 Morphology and physiology of the epiphyseal growth plate. Folia Histochemica et Cytobiologica 47 5-16. (doi:10.2478/v10042-009-0007-1)
15. Carlton MB, Colledge WH & Evans MJ 1998 Crouzon-like craniofacial dysmorphology in the mouse is caused by an insertional mutation at Published by Bioscientifica Ltd Thematic Review Y XIE and others the Fgf3/Fgf4 locus. Developmental Dynamics 212 242-249. (doi:10.1002/(SICI)1097-0177(199806)212:2!242::AID-AJA8O3.0.CO;2-H)
16. Chang H, Li D, Zhuang L, Nie E, Bouman D, Stewart AK & Chun K 2004 Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis. Leukemia & Lymphoma 45 965-969. (doi:10.1080/10428190310001638832)
17. Chen L, Adar R, Yang X, Monsonego EO, Li C, Hauschka PV, Yayon A & Deng CX 1999 Gly369Cys mutation in mouse FGFR3 causes achon-droplasia by affecting both chondrogenesis and osteogenesis. Journal of Clinical Investigation 104 1517-1525. (doi:10.1172/JCI6690)
18. Chen L, Li C, Qiao W, Xu X & Deng C 2001 A Ser(365)/Cys mutation of fibroblast growth factor receptor 3 in mouse downregulates Ihh/PTHrP signals and causes severe achondroplasia. Human Molecular Genetics 10 457-465. (doi:10.1093/hmg/10.5.457)
19. Chen L, Li D, Li C, Engel A & Deng CX 2003 A Ser252Trp [corrected] substitution in mouse fibroblast growth factor receptor 2 (Fgfr2) results in craniosynostosis. Bone 33 169-178. (doi:10.1016/S8756-3282(03) 00222-9)
20. Chung UI, Lanske B, Lee K, Li E & Kronenberg H 1998 The parathyroid hormone/parathyroid hormone-related peptide receptor coordinates endochondral bone development by directly controlling chondrocyte differentiation. PNAS 95 13030-13035. (doi:10.1073/pnas.95.22.13030)
21. Chung UI, Schipani E, McMahon AP & Kronenberg HM 2001 Indian hedgehog couples chondrogenesis to osteogenesis in endochondral bone development. Journal of Clinical Investigation 107 295-304. (doi:10.1172/JCI11706)
22. Coffin JD, Florkiewicz RZ, Neumann J, Mort-Hopkins T, Dorn GW II, Lightfoot P, German R, Howles PN, Kier A, O'Toole BA et al. 1995 Abnormal bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2) transgenic mice. Molecular Biology of the Cell 6 1861-1873. (doi:10.1091/mbc.6.12.1861)
23. Coleman SJ, Bruce C, Chioni AM, Kocher HM & Grose RP 2014 The ins and outs of fibroblast growth factor receptor signalling. Clinical Science 127 217-231. (doi:10.1042/CS20140100)
24. Colvin JS, Bohne BA, Harding GW, McEwen DG & Ornitz DM 1996 Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nature Genetics 12 390-397. (doi:10.1038/ng0496-390)
25. Cool S, Jackson R, Pincus P, Dickinson I & Nurcombe V 2002 Fibroblast growth factor receptor 4 (FGFR4) expression in newborn murine calvaria and primary osteoblast cultures. International Journal of Developmental Biology 46 519-523.
26. Coussens AK & van Daal A 2005 Linkage disequilibrium analysis identifies an FGFR1 haplotype-tag SNP associated with normal variation in craniofacial shape. Genomics 85 563-573. (doi:10.1016/j.ygeno.2005.02.002)
27. Coutu DL, Francois M & Galipeau J 2011 Inhibition of cellular senescence by developmentally regulated FGF receptors in mesenchymal stem cells. Blood 117 6801-6812. (doi:10.1182/blood-2010-12-321539)
28. Cowan CM, Quarto N, Warren SM, Salim A & Longaker MT 2003 Age-related changes in the biomolecular mechanisms of calvarial osteoblast biology affect fibroblast growth factor-2 signaling and osteogenesis. Journal of Biological Chemistry 278 32005-32013. (doi:10.1074/jbc.M304698200)
29. Cunningham ML, Seto ML, Ratisoontorn C, Heike CL & Hing AV 2007 Syndromic craniosynostosis: from history to hydrogen bonds. Orthodontics & Craniofacial Research 10 67-81. (doi:10.1111/j.1601- 6343.2007.00389.x)
30. Dailey L, Laplantine E, Priore R & Basilico C 2003 A network of transcriptional and signaling events is activated by FGF to induce chondrocyte growth arrest and differentiation. Journal of Cell Biology 1611053-1066. (doi:10.1083/jcb.200302075)
31. Dailey L, Ambrosetti D, Mansukhani A & Basilico C 2005 Mechanisms underlying differential responses to FGF signaling. Cytokine & Growth Factor Reviews 16 233-247. (doi:10.1016/j.cytogfr.2005.01.007) FGF signaling on growth plate
32. Delezoide AL, Benoist-Lasselin C, Legeai-Mallet L, Le Merrer M, Munnich A, Vekemans M & Bonaventure J 1998 Spatio-temporal expression of FGFR 1, 2 and 3 genes during human embryo-fetal ossification. Mechanisms of Development 77 19-30. (doi:10.1016/S0925-4773(98)00133-6)
33. Dell'Accio F, De Bari C & Luyten FP 2001 Molecular markers predictive of the capacity of expanded human articular chondrocytes to form stable cartilage in vivo. Arthritis and Rheumatism 44 1608-1619. (doi:10.1002/1529-0131(200107)44:7!1608::AID-ART284O3.0.CO;2-T)
34. Deng CX, Wynshaw-Boris A, Shen MM, Daugherty C, Ornitz DM & Leder P 1994 Murine FGFR-1 is required for early postimplantation growth and axial organization. Genes and Development 8 3045-3057. (doi:10.1101/gad.8.24.3045)
35. Deng C, Wynshaw-Boris A, Zhou F, Kuo A & Leder P 1996 Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84 911-921. (doi:10.1016/S0092-8674(00)81069-7)
36. Donate-Correa J, Muros-de-Fuentes M, Mora-Fernandez C & Navarro- Gonzalez JF 2012 FGF23/Klotho axis: phosphorus, mineral metabolism and beyond. Cytokine & Growth Factor Reviews 23 37-46. (doi:10.1016/j. cytogfr.2012.01.004)
37. Dooley J, Erickson M, Larochelle WJ, Gillard GO & Farr AG 2007 FGFR2IIIb signaling regulates thymic epithelial differentiation. Developmental Dynamics 236 3459-3471. (doi:10.1002/dvdy.21364)
38. Du X, Xie Y, Xian CJ & Chen L 2012 Role of FGFs/FGFRs in skeletal development and bone regeneration. Journal of Cellular Physiology 227 3731-3743. (doi:10.1002/jcp.24083)
39. El-Hoss J, Kolind M, Jackson MT, Deo N, Mikulec K, McDonald MM, Little CB, Little DG & Schindeler A 2014 Modulation of endochondral ossification by MEK inhibitors PD0325901 and AZD6244 (Selumetinib). Bone 59 151-161. (doi:10.1016/j.bone.2013.11.013)
40. Elo T, Sipila P, Valve E, Kujala P, Toppari J, Poutanen M & Harkonen P 2012 Fibroblast growth factor 8b causes progressive stromal and epithelial changes in the epididymis and degeneration of the seminiferous epithelium in the testis of transgenic mice. Biology of Reproduction 86 157, 151-112. (doi:10.1095/biolreprod.111.097352)
41. Eswarakumar VP, Monsonego-Ornan E, Pines M, Antonopoulou I, Morriss-Kay GM & Lonai P 2002 The IIIc alternative of Fgfr2 is a positive regulator of bone formation. Development 129 3783-3793.
42. Eswarakumar VP, Horowitz MC, Locklin R, Morriss-Kay GM & Lonai P 2004 A gain-of-function mutation of Fgfr2c demonstrates the roles of this receptor variant in osteogenesis. PNAS 101 12555-12560. (doi:10.1073/ pnas.0405031101)
43. Eswarakumar VP, Lax I & Schlessinger J 2005 Cellular signaling by fibroblast growth factor receptors. Cytokine & Growth Factor Reviews 16 139-149. (doi:10.1016/j.cytogfr.2005.01.001)
44. Fallon JF, Lopez A, Ros MA, Savage MP, Olwin BB & Simandl BK 1994 FGF-2: apical ectodermal ridge growth signal for chick limb development. Science 264 104-107. (doi:10.1126/science.7908145)
45. Fei Y & Hurley MM 2012 Role of fibroblast growth factor 2 and Wnt signaling in anabolic effects of parathyroid hormone on bone formation. Journal of Cellular Physiology 227 3539-3545. (doi:10.1002/ jcp.24075)
46. Fei Y, Xiao L & Hurley MM 2011 The impaired bone anabolic effect of PTH in the absence of endogenous FGF2 is partially due to reduced ATF4 expression. Biochemical and Biophysical Research Communications 412 160-164. (doi:10.1016/j.bbrc.2011.07.066)
47. Feteih R, Tassinari MS & Lian JB 1990 Effect of sodium warfarin on vitamin K-dependent proteins and skeletal development in the rat fetus. Journal of Bone and Mineral Research 5 885-894. (doi:10.1002/ jbmr.5650050813)
48. Foldynova-Trantirkova S, Wilcox WR & Krejci P 2012 Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias. Human Mutation 33 29-41. (doi:10.1002/humu.21636)
49. Fortin D, Rom E, Sun H, Yayon A & Bansal R 2005 Distinct fibroblast growth factor (FGF)/FGF receptor signaling pairs initiate diverse cellular Thematic Review Y XIE and others responses in the oligodendrocyte lineage. Journal of Neuroscience 25 7470-7479. (doi:10.1523/JNEUROSCI.2120-05.2005)
50. de Frutos CA, Vega S, Manzanares M, Flores JM, Huertas H, Martinez-Frias ML & Nieto MA 2007 Snail1 is a transcriptional effector of FGFR3 signaling during chondrogenesis and achondroplasias. Developmental Cell 13 872-883. (doi:10.1016/j.devcel.2007.09.016)
51. Fukumoto S & Yamashita T 2007 FGF23 is a hormone-regulating phosphate metabolism - unique biological characteristics of FGF23. Bone 40 1190-1195. (doi:10.1016/j.bone.2006.12.062)
52. Garcia S, Dirat B, Tognacci T, Rochet N, Mouska X, Bonnafous S, Patouraux S, Tran A, Gual P, Le Marchand-Brustel Y et al. 2013 Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice. Science Translational Medicine 5 203-124. (doi:10.1126/ scitranslmed.3006247)
53. Garofalo S, Kliger-Spatz M, Cooke JL, Wolstin O, Lunstrum GP, Moshkovitz SM, Horton WA & Yayon A 1999 Skeletal dysplasia and defective chondrocyte differentiation by targeted overexpression of fibroblast growth factor 9 in transgenic mice. Journal of Bone and Mineral Research 141909-1915. (doi:10.1359/jbmr.1999.14.11.1909)
54. Gattineni J, Bates C, Twombley K, Dwarakanath V, Robinson ML, Goetz R, Mohammadi M & Baum M 2009 FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predomi-nantly via FGF receptor 1. American Journal of Physiology. Renal Physiology 297 F282-F291. (doi:10.1152/ajprenal.90742.2008)
55. Gattineni J, Twombley K, Goetz R, Mohammadi M & Baum M 2011 Regulation of serum 1,25(OH)2vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4. American Journal of Physiology. Renal Physiology 301 F371-F377. (doi:10.1152/ajprenal.00740.2010)
56. Gattineni J, Alphonse P, Zhang Q, Mathews N, Bates CM & Baum M 2014 Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4. American Journal of Physiology. Renal Physiology 306 F351-F358. (doi:10.1152/ajprenal.00232.2013)
57. Gong SG 2012 The Fgfr2W290R mouse model of Crouzon syndrome. Child's Nervous System 28 1495-1503. (doi:10.1007/s00381-012-1792-y)
58. Gong SG 2014 Isoforms of receptors of fibroblast growth factors. Journal of Cellular Physiology [in press]. (doi:10.1002/jcp.24649)
59. Grillo L, Greco D, Pettinato R, Avola E, Potenza N, Castiglia L, Spalletta A, Amata S, Di Benedetto D, Luciano D et al. 2014 Increased FGF3 and FGF4 gene dosage is a risk factor for craniosynostosis. Gene 534 435-439. (doi:10.1016/j.gene.2013.09.120)
60. Grimsrud CD, Romano PR, D'Souza M, Puzas JE, Schwarz EM, Reynolds PR, Roiser RN & O'Keefe RJ 2001 BMP signaling stimulates chondrocyte maturation and the expression of Indian hedgehog. Journal of Orthopaedic Research 19 18-25. (doi:10.1016/S0736-0266(00)00017-6)
61. Gunhaga L, Marklund M, Sjodal M, Hsieh JC, Jessell TM & Edlund T 2003 Specification of dorsal telencephalic character by sequential Wnt and FGF signaling. Nature Neuroscience 6 701-707. (doi:10.1038/nn1068)
62. Guo X, Mak KK, Taketo MM & Yang Y 2009 The Wnt/b-catenin pathway interacts differentially with PTHrP signaling to control chondrocyte hypertrophy and final maturation. PLoS ONE 4 e6067. (doi:10.1371/ journal.pone.0006067)
63. Hadari Y & Schlessinger J 2009 FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma. Journal of Clinical Investigation 119 1077-1079. (doi:10.1172/JCI38948)
64. Hafner C, Toll A, Fernandez-Casado A, Earl J, Marques M, Acquadro F, Mendez-Pertuz M, Urioste M, Malats N, Burns JE et al. 2010 Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors. PNAS 107 20780-20785. (doi:10.1073/pnas.1008365107)
65. Hajihosseini MK, Wilson S, De Moerlooze L & Dickson C 2001 A splicing switch and gain-of-function mutation in FgfR2-IIIc hemizygotes causes Apert/Pfeiffer-syndrome-like phenotypes. PNAS 98 3855-3860. (doi:10.1073/pnas.071586898)
66. Hajihosseini MK, Lalioti MD, Arthaud S, Burgar HR, Brown JM, Twigg SR, Wilkie AO & Heath JK 2004 Skeletal development is regulated by FGF signaling on growth plate fibroblast growth factor receptor 1 signalling dynamics. Development 131325-335. (doi:10.1242/dev.00940)
67. Harada D, Yamanaka Y, Ueda K, Nishimura R, Morishima T, Seino Y & Tanaka H 2007 Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCg-activated STAT1. Bone 41 273-281. (doi:10.1016/j.bone.2006.11.030)
68. Harada M, Murakami H, Okawa A, Okimoto N, Hiraoka S, Nakahara T, Akasaka R, Shiraishi Y, Futatsugi N, Mizutani-Koseki Y et al. 2009 FGF9 monomer-dimer equilibrium regulates extracellular matrix affinity and tissue diffusion. Nature Genetics 41 289-298. (doi:10.1038/ng.316)
69. Hattori T, Muller C, Gebhard S, Bauer E, Pausch F, Schlund B, Bosl MR, Hess A, Surmann-Schmitt C, von der Mark H et al. 2010 SOX9 is a major negative regulator of cartilage vascularization, bone marrow formation and endochondral ossification. Development 137 901-911. (doi:10.1242/dev.045203)
70. He X, Xie F & Ren ZR 2012 Rapid detection of G1138A and G1138C mutations of the FGFR3 gene in patients with achondroplasia using high-resolution melting analysis. Genetic Testing and Molecular Biomarkers 16 297-301. (doi:10.1089/gtmb.2011.0113)
71. Henderson JE, Naski MC, Aarts MM, Wang D, Cheng L, Goltzman D & Ornitz DM 2000 Expression of FGFR3 with the G380R achondroplasia mutation inhibits proliferation and maturation of CFK2 chondrocytic cells. Journal of Bone and Mineral Research 15 155-165. (doi:10.1359/ jbmr.2000.15.1.155)
72. Huch K, Kleffner S, Stove J, Puhl W, Gunther KP & Brenner RE 2003 PTHrP, PTHr, and FGFR3 are involved in the process of endochondral ossification in human osteophytes. Histochemistry and Cell Biology 119 281-287. (doi:10.1007/s00418-003-0519-2)
73. Hung IH, Yu K, Lavine KJ & Ornitz DM 2007 FGF9 regulates early hypertrophic chondrocyte differentiation and skeletal vascularization in the developing stylopod. Developmental Biology 307 300-313. (doi:10.1016/j.ydbio.2007.04.048)
74. Hurley MM, Okada Y, Xiao L, Tanaka Y, Ito M, Okimoto N, Nakamura T, Rosen CJ, Doetschman T & Coffin JD 2006 Impaired bone anabolic response to parathyroid hormone in Fgf2K/K and Fgf2C/K mice. Biochemical and Biophysical Research Communications 341 989-994. (doi:10.1016/j.bbrc.2006.01.044)
75. Iseki S, Wilkie AO, Heath JK, Ishimaru T, Eto K & Morriss-Kay GM 1997 Fgfr2 and osteopontin domains in the developing skull vault are mutually exclusive and can be altered by locally applied FGF2. Development 124 3375-3384.
76. Iseki S, Wilkie AO & Morriss-Kay GM 1999 Fgfr1 and Fgfr2 have distinct differentiation- and proliferation-related roles in the developing mouse skull vault. Development 126 5611-5620.
77. Ishida K & Haudenschild DR 2013 Interactions between FGF21 and BMP-2 in osteogenesis. Biochemical and Biophysical Research Communications 432677-682. (doi:10.1016/j.bbrc.2013.02.019)
78. Itoh N & Ornitz DM 2008 Functional evolutionary history of the mouse Fgf gene family. Developmental Dynamics 237 18-27. (doi:10.1002/dvdy.21388)
79. Iwata T, Chen L, Li C, Ovchinnikov DA, Behringer RR, Francomano CA & Deng CX 2000 A neonatal lethal mutation in FGFR3 uncouples prolife-ration and differentiation of growth plate chondrocytes in embryos. Human Molecular Genetics 9 1603-1613. (doi:10.1093/hmg/9.11.1603)
80. Iwata T, Li CL, Deng CX & Francomano CA 2001 Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice. Human Molecular Genetics 10 1255-1264. (doi:10.1093/hmg/10.12.1255)
81. Jacob AL, Smith C, Partanen J & Ornitz DM 2006 Fibroblast growth factor receptor 1 signaling in the osteo-chondrogenic cell lineage regulates sequential steps of osteoblast maturation. Developmental Biology 57 315-328. (doi:10.1016/j.ydbio.2006.05.031)
82. Jarzabek K, Wolczynski S, Lesniewicz R, Plessis G & Kottler ML 2012 Evidence that FGFR1 loss-of-function mutations may cause variable skeletal malformations in patients with Kallmann syndrome. Advances in Medical Sciences 57 314-321. (doi:10.2478/v10039-012-0036-4) Thematic Review Y XIE and others
83. Jin M, Yu Y, Qi H, Xie Y, Su N, Wang X, Tan Q, Luo F, Zhu Y, Wang Q et al. 2012a A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia. Human Molecular Genetics 21 5443-5455. (doi:10.1093/ hmg/dds390)
84. Jin M, Du X & Chen L 2012b Cross-talk between FGF and other cytokine signalling pathways during endochondral bone development. Cell Biology International 36 691-696. (doi:10.1042/CBI20110352)
85. Jonquoy A, Mugniery E, Benoist-Lasselin C, Kaci N, Le Corre L, Barbault F, Girard AL, Le Merrer Y, Busca P, Schibler L et al. 2012 A novel tyrosine kinase inhibitor restores chondrocyte differentiation and promotes bone growth in a gain-of-function Fgfr3 mouse model. Human Molecular Genetics 21 841-851. (doi:10.1093/hmg/ddr514)
86. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O et al. 2003 Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. New England Journal of Medicine 348 1656-1663. (doi:10.1056/NEJMoa020881)
87. Kamath AV, Lu D, Gupta P, Jin D, Xin Y, Brady A, Stephan JP, Li H, Tien J, Qing J et al. 2012 Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma. Cancer Chemotherapy and Pharmacology 69 1071-1078. (doi:10.1007/s00280-011-1807-5)
88. Karsenty G & Wagner EF 2002 Reaching a genetic and molecular understanding of skeletal development. Developmental Cell 2 389-406. (doi:10.1016/S1534-5807(02)00157-0)
89. Karsenty G, Kronenberg HM & Settembre C 2009 Genetic control of bone formation. Annual Review of Cell and Developmental Biology 25 629-648. (doi:10.1146/annurev.cellbio.042308.113308)
90. Kawai M, Kinoshita S, Kimoto A, Hasegawa Y, Miyagawa K, Yamazaki M, Ohata Y, Ozono K & Michigami T 2013 FGF23 suppresses chondrocyte proliferation in the presence of soluble a-Klotho both in vitro and in vivo. Journal of Biological Chemistry 288 2414-2427. (doi:10.1074/jbc.M112.410043)
91. Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ, Belch AR & Pilarski LM 2003 In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 101 1520-1529. (doi:10.1182/blood-2002-06-1675)
92. Kerkhofs J, Roberts SJ, Luyten FP, Van Oosterwyck H & Geris L 2012 Relating the chondrocyte gene network to growth plate morphology: from genes to phenotype. PLoS ONE 7 e34729. (doi:10.1371/journal.pone.0034729)
93. King N, Odom TW, Sampson HW & Yersin AG 1991 The effect of in ovo boron supplementation on bone mineralization of the vitamin D-deficient chicken embryo. Biological Trace Element Research 31 223-233. (doi:10.1007/BF02990193)
94. Kobayashi T, Chung UI, Schipani E, Starbuck M, Karsenty G, Katagiri T, Goad DL, Lanske B & Kronenberg HM 2002 PTHrP and Indian hedgehog control differentiation of growth plate chondrocytes at multiple steps. Development 129 2977-2986.
95. Krejci P 2014 The paradox of FGFR3 signaling in skeletal dysplasia: why chondrocytes growth arrest while other cells over proliferate. Mutation Research. Reviews in Mutation Research 759 40-48. (doi:10.1016/j.mrrev.2013.11.001)
96. Krejci P, Bryja V, Pachernik J, Hampl A, Pogue R, Mekikian P & Wilcox WR 2004 FGF2 inhibits proliferation and alters the cartilage-like phenotype of RCS cells. Experimental Cell Research 297 152-164. (doi:10.1016/j.yexcr.2004.03.011)
97. Krejci P, Masri B, Fontaine V, Mekikian PB, Weis M, Prats H & Wilcox WR 2005 Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis. Journal of Cell Science 118 5089-5100. (doi:10.1242/jcs.02618)
98. Krejci P, Krakow D, Mekikian PB & Wilcox WR 2007 Fibroblast growth factors 1, 2, 17, and 19 are the predominant FGF ligands expressed in FGF signaling on growth plate human fetal growth plate cartilage. Pediatric Research 61 267-272. (doi:10.1203/pdr.0b013e318030d157)
99. Krejci P, Prochazkova J, Smutny J, Chlebova K, Lin P, Aklian A, Bryja V, Kozubik A&WilcoxWR2010FGFR3signalinginducesareversiblesenescence phenotype in chondrocytes similar to oncogene-induced premature senescence. Bone 47 102-110. (doi:10.1016/j.bone.2010.03.021)
100. Krejci P, Aklian A, Kaucka M, Sevcikova E, Prochazkova J, Masek JK, Mikolka P, Pospisilova T, Spoustova T, Weis M et al. 2012 Receptor tyrosine kinases activate canonical WNT/b-catenin signaling via MAP kinase/LRP6 pathway and direct b-catenin phosphorylation. PLoS ONE 7 e35826. (doi:10.1371/journal.pone.0035826)
101. Kyono A, Avishai N, Ouyang Z, Landreth GE & Murakami S 2012 FGF and ERK signaling coordinately regulate mineralization-related genes and play essential roles in osteocyte differentiation. Journal of Bone and Mineral Metabolism 30 19-30. (doi:10.1007/s00774-011-0288-2)
102. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, Rivadeneira F, Willer CJ, Jackson AU, Vedantam S, Raychaudhuri S et al. 2010 Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 467 832-838. (doi:10.1038/nature09410)
103. Larbuisson A, Dalcq J, Martial JA & Muller M 2013 Fgf receptors Fgfr1a and Fgfr2 control the function of pharyngeal endoderm in late cranial cartilage development. Differentiation 86 192-206. (doi:10.1016/j.diff.2013.07.006)
104. Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Juppner H & Jonsson KB 2004 Transgenic mice expressing fibroblast growth factor 23 under the control of the a1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145 3087-3094. (doi:10.1210/en.2003-1768)
105. Lazarus JE, Hegde A, Andrade AC, Nilsson O & Baron J 2007 Fibroblast growth factor expression in the postnatal growth plate. Bone 40 577-586. (doi:10.1016/j.bone.2006.10.013)
106. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N, Nagy A, Roos KP & Iruela-Arispe ML 2007 Autocrine VEGF signaling is required for vascular homeostasis. Cell 130 691-703. (doi:10.1016/j.cell.2007.06.054)
107. Lemonnier J, Hay E, Delannoy P, Fromigue O, Lomri A, Modrowski D & Marie PJ 2001 Increased osteoblast apoptosis in Apert craniosynostosis: role of protein kinase C and interleukin-1. American Journal of Pathology 1581833-1842. (doi:10.1016/S0002-9440(10)64139-9)
108. Leung VY, Gao B, Leung KK, Melhado IG, Wynn SL, Au TY, Dung NW, Lau JY, Mak AC, Chan D et al. 2011 SOX9 governs differentiation stage-specific gene expression in growth plate chondrocytes via direct concomitant transactivation and repression. PLoS Genetics 7 e1002356. (doi:10.1371/journal.pgen.1002356)
109. L'Hote CG & Knowles MA 2005 Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Experimental Cell Research 304 417-431. (doi:10.1016/j.yexcr.2004.11.012)
110. Li C, Chen L, Iwata T, Kitagawa M, Fu XY & Deng CX 1999 A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. Human Molecular Genetics 8 35-44. (doi:10.1093/hmg/8.1.35)
111. Li M, Seki Y, Freitas PH, Nagata M, Kojima T, Sultana S, Ubaidus S, Maeda T, Shimomura J, Henderson JE et al. 2010 FGFR3 down-regulates PTH/PTHrP receptor gene expression by mediating JAK/STAT signaling in chondrocytic cell line. Journal of Electron Microscopy 59 227-236. (doi:10.1093/jmicro/dfq002)
112. Li H, Martin A, David V & Quarles LD 2011a Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype. American Journal of Physiology. Endocrinology and Metabolism 300 E508-E517. (doi:10.1152/ajpendo.00499.2010)
113. Li H, Haurigot V, Doyon Y, Li T, Wong SY, Bhagwat AS, Malani N, Anguela XM, Sharma R, Ivanciu L et al. 2011b In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 475 217-221. (doi:10.1038/nature10177)
114. Lin RZ & Melero-Martin JM 2012 Fibroblast growth factor-2 facilitates rapid anastomosis formation between bioengineered human vascular Thematic Review Y XIE and others networks and living vasculature. Methods 56 440-451. (doi:10.1016/j.ymeth.2012.01.006)
115. Lin JM, Callon KE, Lin JS, Watson M, Empson V, Tong PC, Grey A, Naot D, Green CR, Reid IR et al. 2009 Actions of fibroblast growth factor-8 in bone cells in vitro. American Journal of Physiology. Endocrinology and Metabolism 297 E142-E150. (doi:10.1152/ajpendo.90743.2008)
116. Liu Z, Xu J, Colvin JS & Ornitz DM 2002 Coordination of chondrogenesis and osteogenesis by fibroblast growth factor 18. Genes and Development 16859-869. (doi:10.1101/gad.965602)
117. Liu S, Zhou J, Tang W, Jiang X, Rowe DW & Quarles LD 2006 Pathogenic role of Fgf23 in Hyp mice. American Journal of Physiology. Endocrinology and Metabolism 291 E38-E49. (doi:10.1152/ajpendo.00008.2006)
118. Liu Z, Lavine KJ, Hung IH & Ornitz DM 2007 FGF18 is required for early chondrocyte proliferation, hypertrophy and vascular invasion of the growth plate. Developmental Biology 302 80-91. (doi:10.1016/j.ydbio. 2006.08.071)
119. Lokody I 2014 Genetic therapies: correcting genetic defects with CRISPR-Cas9. Nature Reviews. Genetics 15 63. (doi:10.1038/nrg3656)
120. Lomri A, Lemonnier J, Hott M, de Parseval N, Lajeunie E, Munnich A, Renier D & Marie PJ 1998 Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor 2 mutations in Apert syndrome. Journal of Clinical Investigation 101 1310-1317. (doi:10.1172/JCI119886)
121. Lomri A, Lemonnier J, Delannoy P & Marie PJ 2001 Increased expression of protein kinase Ca, interleukin-1a, and RhoA guanosine 50-tripho-sphatase in osteoblasts expressing the Ser252Trp fibroblast growth factor 2 receptor Apert mutation: identification by analysis of complementary DNA microarray. Journal of Bone and Mineral Research 16705-712. (doi:10.1359/jbmr.2001.16.4.705)
122. Long F & Ornitz DM 2013 Development of the endochondral skeleton. Cold Spring Harbor Perspectives in Biology 5 a008334. (doi:10.1101/cshperspect.a008334)
123. Lorget F, Kaci N, Peng J, Benoist-Lasselin C, Mugniery E, Oppeneer T, Wendt DJ, Bell SM, Bullens S, Bunting S et al. 2012 Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. American Journal of Human Genetics 91 1108-1114. (doi:10.1016/j.ajhg.2012.10.014)
124. Lu Y & Feng JQ 2011 FGF23 in skeletal modeling and remodeling. Current Osteoporosis Reports 9 103-108. (doi:10.1007/s11914-011-0053-4)
125. Lu X, Su N, Yang J, Huang W, Li C, Zhao L, He Q, Du X, Shen Y, Chen B et al. 2009 Fibroblast growth factor receptor 1 regulates the differentiation and activation of osteoclasts through Erk1/2 pathway. Biochemical and Biophysical Research Communications 390 494-499. (doi:10.1016/j.bbrc.2009.09.123)
126. Lui JC, Nilsson O, Chan Y, Palmer CD, Andrade AC, Hirschhorn JN & Baron J 2012 Synthesizing genome-wide association studies and expression microarray reveals novel genes that act in the human growth plate to modulate height. Human Molecular Genetics 21 5193-5201. (doi:10.1093/hmg/dds347)
127. Ma N, Liao B, Zhang H, Wang L, Shan Y, Xue Y, Huang K, Chen S, Zhou X, Chen Y et al. 2013 Transcription activator-like effector nuclease (TALEN)-mediated gene correction in integration-free b-thalassemia induced pluripotent stem cells. Journal of Biological Chemistry 288 34671-34679. (doi:10.1074/jbc.M113.496174)
128. Maes C, Kobayashi T, Selig MK, Torrekens S, Roth SI, Mackem S, Carmeliet G&KronenbergHM2010Osteoblastprecursors,butnotmature osteoblasts, move into developing and fractured bones along with invading blood vessels. Developmental Cell 19 329-344. (doi:10.1016/j.devcel.2010.07.010)
129. Mangion J, Rahman N, Edkins S, Barfoot R, Nguyen T, Sigurdsson A, Townend JV, Fitzpatrick DR, Flanagan AM & Stratton MR 1999 The gene for cherubism maps to chromosome 4p16.3. American Journal of Human Genetics 65 151-157. (doi:10.1086/302454)
130. Mansukhani A, Bellosta P, Sahni M & Basilico C 2000 Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces FGF signaling on growth plate apoptosis in osteoblasts. Journal of Cell Biology 149 1297-1308. (doi:10.1083/jcb.149.6.1297)
131. Mansukhani A, Ambrosetti D, Holmes G, Cornivelli L & Basilico C 2005 Sox2 induction by FGF and FGFR2 activating mutations inhibits Wnt signaling and osteoblast differentiation. Journal of Cell Biology 168 1065-1076. (doi:10.1083/jcb.200409182)
132. Mariani FV, Ahn CP & Martin GR 2008 Genetic evidence that FGFs have an instructive role in limb proximal-distal patterning. Nature 453 401-405. (doi:10.1038/nature06876)
133. Marie PJ, Coffin JD & Hurley MM 2005 FGF and FGFR signaling in chondrodysplasias and craniosynostosis. Journal of Cellular Biochemistry 96888-896. (doi:10.1002/jcb.20582)
134. Marie PJ, Miraoui H & Severe N 2012 FGF/FGFR signaling in bone formation: progress and perspectives. Growth Factors 30 117-123. (doi:10.3109/08977194.2012.656761)
135. Martin GR 1998 The roles of FGFs in the early development of vertebrate limbs. Genes and Development 12 1571-1586. (doi:10.1101/gad.12.11.1571)
136. Martinez-Frias ML, de Frutos CA, Bermejo E & Nieto MA 2010 Review of the recently defined molecular mechanisms underlying thanatophoric dysplasia and their potential therapeutic implications for achondroplasia. American Journal of Medical Genetics. Part A 152A 245-255. (doi:10.1002/ajmg.a.33188)
137. Matsushita T, Wilcox WR, Chan YY, Kawanami A, Bukulmez H, Balmes G, Krejci P, Mekikian PB, Otani K, Yamaura I et al. 2009 FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway. Human Molecular Genetics 18 227-240. (doi:10.1093/hmg/ddn339)
138. Matsushita M, Kitoh H, Ohkawara B, Mishima K, Kaneko H, Ito M, Masuda A, Ishiguro N & Ohno K 2013 Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia. PLoS One 8 e81569. (doi:10.1371/journal.pone.0081569)
139. Mayahara H, Ito T, Nagai H, Miyajima H, Tsukuda R, Taketomi S, Mizoguchi J & Kato K 1993 In vivo stimulation of endosteal bone formation by basic fibroblast growth factor in rats. Growth Factors 9 73-80. (doi:10.3109/08977199308991583)
140. Mendelsohn AR & Larrick JW 2012 Fibroblast growth factor-21 is a promising dietary restriction mimetic. Rejuvenation Research 15 624-628. (doi:10.1089/rej.2012.1392)
141. Merrill AE, Sarukhanov A, Krejci P, Idoni B, Camacho N, Estrada KD, Lyons KM, Deixler H, Robinson H, Chitayat D et al. 2012 Bent bone dysplasia-FGFR2 type, a distinct skeletal disorder, has deficient canonical FGF signaling. American Journal of Human Genetics 90 550-557. (doi:10.1016/j.ajhg.2012.02.005)
142. Meyers GA, Orlow SJ, Munro IR, Przylepa KA & Jabs EW 1995 Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nature Genetics 11 462-464. (doi:10.1038/ng1295-462)
143. Michigami T 2013 Regulatory mechanisms for the development of growth plate cartilage. Cellular and Molecular Life Sciences 70 4213-4221. (doi:10.1007/s00018-013-1346-9)
144. Milunsky JM, Zhao G, Maher TA, Colby R & Everman DB 2006 LADD syndrome is caused by FGF10 mutations. Clinical Genetics 69 349-354. (doi:10.1111/j.1399-0004.2006.00597.x)
145. Minina E, Wenzel HM, Kreschel C, Karp S, Gaffield W, McMahon AP & Vortkamp A 2001 BMP and Ihh/PTHrP signaling interact to coordinate chondrocyte proliferation and differentiation. Development 128 4523-4534.
146. Minina E, Kreschel C, Naski MC, Ornitz DM & Vortkamp A 2002 Interaction of FGF, Ihh/Pthlh, and BMP signaling integrates chondrocyte proliferation and hypertrophic differentiation. Developmental Cell 3 439-449. (doi:10.1016/S1534-5807(02)00261-7)
147. Minina E, Schneider S, Rosowski M, Lauster R & Vortkamp A 2005 Expression of Fgf and Tgfbeta signaling related genes during embryonic Thematic Review Y XIE and others endochondral ossification. Gene Expression Patterns 6 102-109. (doi:10.1016/j.modgep.2005.04.012)
148. Montero A, Okada Y, Tomita M, Ito M, Tsurukami H, Nakamura T, Doetschman T, Coffin JD & Hurley MM 2000 Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. Journal of Clinical Investigation 105 1085-1093. (doi:10.1172/JCI8641)
149. Moon AM & Capecchi MR 2000 Fgf8 is required for outgrowth and patterning of the limbs. Nature Genetics 26 455-459. (doi:10.1038/82601)
150. Moon AM, Boulet AM & Capecchi MR 2000 Normal limb development in conditional mutants of Fgf4. Development 127 989-996.
151. Morita J, Nakamura M, Kobayashi Y, Deng CX, Funato N & Moriyama K 2014 Soluble form of FGFR2 with S252W partially prevents craniosynostosis of the Apert mouse model. Developmental Dynamics 243 560-567. (doi:10.1002/dvdy.24099)
152. Muenke M, Schell U, Hehr A, Robin NH, Losken HW, Schinzel A, Pulleyn LJ, Rutland P, Reardon W, Malcolm S et al. 1994 A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome. Nature Genetics 8 269-274. (doi:10.1038/ng1194-269)
153. Muenke M, Gripp KW, McDonald-McGinn DM, Gaudenz K, Whitaker LA, Bartlett SP, Markowitz RI, Robin NH, Nwokoro N, Mulvihill JJ et al. 1997 A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome. American Journal of Human Genetics 60 555-564.
154. Mugniery E, Dacquin R, Marty C, Benoist-Lasselin C, de Vernejoul MC, Jurdic P, Munnich A, Geoffroy V & Legeai-Mallet L 2012 An activating Fgfr3 mutation affects trabecular bone formation via a paracrine mechanism during growth. Human Molecular Genetics 21 2503-2513. (doi:10.1093/hmg/dds065)
155. Murakami H, Okawa A, Yoshida H, Nishikawa S, Moriya H & Koseki H 2002 Elbow knee synostosis (Eks): a new mutation on mouse chromosome 14. Mammalian Genome 13 341-344. (doi:10.1007/s00335-001-2143-6)
156. Murakami S, Balmes G, McKinney S, Zhang Z, Givol D & de Crombrugghe B 2004 Constitutive activation of MEK1 in chondrocytes causes Stat1- independent achondroplasia-like dwarfism and rescues the Fgfr3- deficient mouse phenotype. Genes and Development 18 290-305. (doi:10.1101/gad.1179104)
157. Nakamura T, Hanada K, Tamura M, Shibanushi T, Nigi H, Tagawa M, Fukumoto S & Matsumoto T 1995 Stimulation of endosteal bone formation by systemic injections of recombinant basic fibroblast growth factor in rats. Endocrinology 136 1276-1284. (doi:10.1210/endo.136.3.7867582)
158. Naski MC, Colvin JS, Coffin JD & Ornitz DM 1998 Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Development 125 4977-4988.
159. Nowroozi N, Raffioni S, Wang T, Apostol BL, Bradshaw RA & Thompson LM 2005 Sustained ERK1/2 but not STAT1 or 3 activation is required for thanatophoric dysplasia phenotypes in PC12 cells. Human Molecular Genetics 14 1529-1538. (doi:10.1093/hmg/ddi161)
160. Ochiai H, Miyamoto T, Kanai A, Hosoba K, Sakuma T, Kudo Y, Asami K, Ogawa A, Watanabe A, Kajii T et al. 2014 TALEN-mediated single-base-pair editing identification of an intergenic mutation upstream of BUB1B as causative of PCS (MVA) syndrome. PNAS 111 1461-1466. (doi:10.1073/pnas.1317008111)
161. Ogata H, Wada Y & Akizawa T 2008 Role of kidney in calcium homeostasis and premature aging. Clinical Calcium 18 942-946.
162. Ohbayashi N, Shibayama M, Kurotaki Y, Imanishi M, Fujimori T, Itoh N & Takada S 2002 FGF18 is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesis. Genes and Development 16 870-879. (doi:10.1101/gad.965702)
163. Ohuchi H, Nakagawa T, Yamamoto A, Araga A, Ohata T, Ishimaru Y, Yoshioka H, Kuwana T, Nohno T, Yamasaki M et al. 1997 The mesenchymal factor, FGF10, initiates and maintains the outgrowth of the chick limb bud through interaction with FGF8, an apical ectodermal factor. Development 124 2235-2244. FGF signaling on growth plate
164. Okada Y, Montero A, Zhang X, Sobue T, Lorenzo J, Doetschman T, Coffin JD & Hurley MM 2003 Impaired osteoclast formation in bone marrow cultures of Fgf2 null mice in response to parathyroid hormone. Journal of Biological Chemistry 278 21258-21266. (doi:10.1074/jbc.M302113200)
165. Olsen BR, Reginato AM & Wang W 2000 Bone development. Annual Review of Cell and Developmental Biology 16 191-220. (doi:10.1146/annurev.cellbio.16.1.191)
166. Omoteyama K & Takagi M 2009 FGF8 regulates myogenesis and induces Runx2 expression and osteoblast differentiation in cultured cells. Journal of Cellular Biochemistry 106 546-552. (doi:10.1002/jcb.22012)
167. Ornitz DM 2005 FGF signaling in the developing endochondral skeleton. Cytokine & Growth Factor Reviews 16 205-213. (doi:10.1016/j.cytogfr.2005.02.003)
168. Ornitz DM & Itoh N 2001 Fibroblast growth factors. Genome Biology 2. REVIEWS3005. (doi:10.1186/gb-2001-2-3-reviews3005)
169. Ornitz DM & Marie PJ 2002 FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes and Development 16 1446-1465. (doi:10.1101/gad.990702)
170. Orr-Urtreger A, Bedford MT, Burakova T, Arman E, Zimmer Y, Yayon A, Givol D & Lonai P 1993 Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2). Developmental Biology 158 475-486. (doi:10.1006/dbio.1993.1205)
171. Ortega N, Behonick DJ & Werb Z 2004 Matrix remodeling during endochondral ossification. Trends in Cell Biology 14 86-93. (doi:10.1016/j.tcb.2003.12.003)
172. Ozasa A, Komatsu Y, Yasoda A, Miura M, Sakuma Y, Nakatsuru Y, Arai H, Itoh N & Nakao K 2005 Complementary antagonistic actions between C-type natriuretic peptide and the MAPK pathway through FGFR-3 in ATDC5 cells. Bone 36 1056-1064. (doi:10.1016/j.bone.2005.03.006)
173. Pannier S, Couloigner V, Messaddeq N, Elmaleh-Berges M, Munnich A, Romand R & Legeai-Mallet L 2009 Activating Fgfr3 Y367C mutation causes hearing loss and inner ear defect in a mouse model of chondrodysplasia. Biochimica et Biophysica Acta 1792 140-147. (doi:10.1016/j.bbadis.2008.11.010)
174. Parafioriti A, del Bianco S, Barisani D, Armiraglio E, Peretti G & Albisetti W 2009 Increased p21 expression in chondrocytes of achondroplasic children independently from the presence of the G380R FGFR3 mutation. Journal of Orthopaedic Science 14 623-630. (doi:10.1007/s00776-009-1355-6)
175. Park MS, Rieger-Fackeldey E, Schanbacher BL, Cook AC, Bauer JA, Rogers LK, Hansen TN, Welty SE & Smith CV 2007 Altered expressions of fibroblast growth factor receptors and alveolarization in neonatal mice exposed to 85% oxygen. Pediatric Research 62 652-657. (doi:10.1203/ PDR.0b013e318159af61)
176. Park J, Park OJ, Yoon WJ, Kim HJ, Choi KY, Cho TJ & Ryoo HM 2012 Functional characterization of a novel FGFR2 mutation, E731K, in craniosynostosis. Journal of Cellular Biochemistry 113 457-464. (doi:10.1002/jcb.23368)
177. Partanen J, Makela TP, Eerola E, Korhonen J, Hirvonen H, Claesson-Welsh L & Alitalo K 1991 FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern. EMBO Journal 10 1347-1354.
178. Perry RW, Rowland GN & Britton WM 1991 Pathology of experimental vitamin D deficiency in turkeys and the effects of various vitamin D supplements. Avian Diseases 35 542-553. (doi:10.2307/1591218)
179. Peters KG, Werner S, Chen G & Williams LT 1992 Two FGF receptor genes are differentially expressed in epithelial and mesenchymal tissues during limb formation and organogenesis in the mouse. Development 114233-243.
180. Peters K, Ornitz D, Werner S & Williams L 1993 Unique expression pattern of the FGF receptor 3 gene during mouse organogenesis. Developmental Biology 155 423-430. (doi:10.1006/dbio.1993.1040)
181. Powers CJ, McLeskey SW & Wellstein A 2000 Fibroblast growth factors, their receptors and signaling. Endocrine-Related Cancer 7 165-197. (doi:10.1677/erc.0.0070165)
182. Thematic Review Y XIE and others Priore R, Dailey L & Basilico C 2006 Downregulation of Akt activity contributes to the growth arrest induced by FGF in chondrocytes. Journal of Cellular Physiology 207 800-808. (doi:10.1002/jcp.20620)
183. Provot S & Schipani E 2005 Molecular mechanisms of endochondral bone development. Biochemical and Biophysical Research Communications 328 658-665. (doi:10.1016/j.bbrc.2004.11.068)
184. Qi H, Jin M, Duan Y, Du X, Zhang Y, Ren F, Wang Y, Tian Q, Wang X, Wang Q et al. 2014 FGFR3 induces degradation of BMP type I receptor to regulate skeletal development. Biochimica et Biophysica Acta 1843 1237-1247. (doi:10.1016/j.bbamcr.2014.03.011)
185. Qing J, Du X, Chen Y, Chan P, Li H, Wu P, Marsters S, Stawicki S, Tien J, Totpal K et al. 2009 Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. Journal of Clinical Investigation 119 1216-1229. (doi:10.1172/JCI38017)
186. Raimann A, Ertl DA, Helmreich M, Sagmeister S, Egerbacher M & Haeusler G 2013 Fibroblast growth factor 23 and Klotho are present in the growth plate. Connective Tissue Research 54 108-117. (doi:10.3109/ 03008207.2012.753879)
187. Raucci A, Laplantine E, Mansukhani A & Basilico C 2004 Activation of the ERK1/2 and p38 mitogen-activated protein kinase pathways mediates fibroblast growth factor-induced growth arrest of chondrocytes. Journal of Biological Chemistry 279 1747-1756. (doi:10.1074/jbc.M310384200)
188. Retting KN, Song B, Yoon BS & Lyons KM 2009 BMP canonical Smad signaling through Smad1 and Smad5 is required for endochondral bone formation. Development 136 1093-1104. (doi:10.1242/dev.029926)
189. van Rhijn BW, van Tilborg AA, Lurkin I, Bonaventure J, de Vries A, Thiery JP, van der Kwast TH, Zwarthoff EC & Radvanyi F 2002 Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. European Journal of Human Genetics 10 819-824. (doi:10.1038/sj.ejhg.5200883)
190. Rice DP, Aberg T, Chan Y, Tang Z, Kettunen PJ, Pakarinen L, Maxson RE & Thesleff I 2000 Integration of FGF and TWIST in calvarial bone and suture development. Development 127 1845-1855.
191. Rice DP, Rice R & Thesleff I 2003 Fgfr mRNA isoforms in craniofacial bone development. Bone 33 14-27. (doi:10.1016/S8756-3282(03)00163-7)
192. Riley BM, Mansilla MA, Ma J, Daack-Hirsch S, Maher BS, Raffensperger LM, Russo ET, Vieira AR, Dode C, Mohammadi M et al. 2007 Impaired FGF signaling contributes to cleft lip and palate. PNAS 104 4512-4517. (doi:10.1073/pnas.0607956104)
193. Rohmann E, Brunner HG, Kayserili H, Uyguner O, Nurnberg G, Lew ED, Dobbie A, Eswarakumar VP, Uzumcu A, Ulubil-Emeroglu M et al. 2006 Mutations in different components of FGF signaling in LADD syndrome. Nature Genetics 38 414-417. (doi:10.1038/ng1757)
194. Sabbieti MG, Agas D, Xiao L, Marchetti L, Coffin JD, Doetschman T & Hurley MM 2009 Endogenous FGF-2 is critically important in PTH anabolic effects on bone. Journal of Cellular Physiology 219 143-151. (doi:10.1002/jcp.21661)
195. Sabbieti MG, Agas D, Marchetti L, Santoni G, Amantini C, Xiao L, Menghi G&Hurley MM, 2010 SignalingpathwaysimplicatedinPGF2aeffectson Fgf2C/C and Fgf2K/K osteoblasts. Journal of Cellular Physiology 224 465-474. (doi:10.1002/jcp.22143)
196. Sahni M, Ambrosetti DC, Mansukhani A, Gertner R, Levy D & Basilico C 1999 FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes and Development 13 1361-1366. (doi:10.1101/gad.13.11.1361)
197. Schwartz Z, Swain LD, Kelly DW, Brooks B & Boyan BD 1992 Regulation of prostaglandin E2 production by vitamin D metabolites in growth zone and resting zone chondrocyte cultures is dependent on cell maturation. Bone 13 395-401. (doi:10.1016/8756-3282(92)90456-7)
198. Sebastian A, Matsushita T, Kawanami A, Mackem S, Landreth GE & Murakami S 2011 Genetic inactivation of ERK1 and ERK2 in chondrocytes promotes bone growth and enlarges the spinal canal. Journal of Orthopaedic Research 29 375-379. (doi:10.1002/jor.21262)
199. Segev O, Chumakov I, Nevo Z, Givol D, Madar-Shapiro L, Sheinin Y, Weinreb M & Yayon A 2000 Restrained chondrocyte proliferation FGF signaling on growth plate and maturation with abnormal growth plate vascularization and ossification in human FGFR-3G380R transgenic mice. Human Molecular Genetics 9 249-258. (doi:10.1093/hmg/9.2.249)
200. Shalhoub V, Ward SC, Sun B, Stevens J, Renshaw L, Hawkins N & Richards WG 2011 Fibroblast growth factor 23 (FGF23) and alpha-klotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit min- eralization. Calcified Tissue International 89 140-150. (doi:10.1007/s00223-011-9501-5)
201. Shams I, Rohmann E, Eswarakumar VP, Lew ED, Yuzawa S, Wollnik B, Schlessinger J & Lax I 2007 Lacrimo-auriculo-dento-digital syndrome is caused by reduced activity of the fibroblast growth factor 10 (FGF10)- FGF receptor 2 signaling pathway. Molecular and Cellular Biology 27 6903-6912. (doi:10.1128/MCB.00544-07)
202. Shapiro IM, Adams CS, Freeman T & Srinivas V 2005 Fate of the hypertrophic chondrocyte: microenvironmental perspectives on apoptosis and survival in the epiphyseal growth plate. Birth Defects Research. Part C, Embryo Today: Reviews 75 330-339. (doi:10.1002/bdrc.20057)
203. Sharma VP, Wall SA, Lord H, Lester T & Wilkie AO 2012 Atypical Crouzon syndrome with a novel Cys62Arg mutation in FGFR2 presenting with sagittal synostosis. Cleft Palate-Craniofacial Journal 49 373-377. (doi:10.1597/11-185)
204. Shimada T & Fukumoto S 2012 FGF23 as a novel therapeutic target. Advances in Experimental Medicine and Biology 728 158-170. (doi:10.1007/978-1-4614-0887-1_10)
205. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S & Yamashita T 2001 Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. PNAS 98 6500-6505. (doi:10.1073/pnas.101545198)
206. Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, Takeuchi Y, Fujita T, Fukumoto S & Yamashita T 2004 FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochemical and Biophysical Research Communications 314 409-414. (doi:10.1016/j.bbrc.2003.12.102)
207. Shinde DN, Elmer DP, Calabrese P, Boulanger J, Arnheim N & Tiemann- Boege I 2013 New evidence for positive selection helps explain the paternal age effect observed in achondroplasia. Human Molecular Genetics 22 4117-4126. (doi:10.1093/hmg/ddt260)
208. Shroff R 2013 Phosphate is a vascular toxin. Pediatric Nephrology 28 583-593. (doi:10.1007/s00467-012-2347-x)
209. Shukla V, Coumoul X, Wang RH, Kim HS & Deng CX 2007 RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis. Nature Genetics 39 1145-1150. (doi:10.1038/ng2096)
210. Shung CY, Ota S, Zhou ZQ, Keene DR & Hurlin PJ 2012 Disruption of a Sox9-b-catenin circuit by mutant Fgfr3 in thanatophoric dysplasia type II. Human Molecular Genetics 21 4628-4644. (doi:10.1093/hmg/dds305)
211. Sirbu IO, Zhao X & Duester G 2008 Retinoic acid controls heart anteroposterior patterning by down-regulating Isl1 through the Fgf8 pathway. Developmental Dynamics 237 1627-1635. (doi:10.1002/dvdy. 21570)
212. Sobue T, Naganawa T, Xiao L, Okada Y, Tanaka Y, Ito M, Okimoto N, Nakamura T, Coffin JD & Hurley MM 2005 Over-expression of fibroblast growth factor-2 causes defective bone mineralization and osteopenia in transgenic mice. Journal of Cellular Biochemistry 95 83-94. (doi:10.1002/ jcb.20389)
213. Su WC, Kitagawa M, Xue N, Xie B, Garofalo S, Cho J, Deng C, Horton WA & Fu XY 1997 Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature 386 288-292. (doi:10.1038/386288a0)
214. Su N, Sun Q, Li C, Lu X, Qi H, Chen S, Yang J, Du X, Zhao L, He Q et al. 2010 Gain-of-function mutation in FGFR3 in mice leads to decreased bone mass by affecting both osteoblastogenesis and osteoclastogenesis. Human Molecular Genetics 19 1199-1210. (doi:10.1093/hmg/ddp590) Thematic Review Y XIE and others
215. Suzuki H, Suda N, Shiga M, Kobayashi Y, Nakamura M, Iseki S & Moriyama K 2012 Apert syndrome mutant FGFR2 and its soluble form reciprocally alter osteogenesis of primary calvarial osteoblasts. Journal of Cellular Physiology 227 3267-3277. (doi:10.1002/jcp.24021)
216. Szebenyi G, Savage MP, Olwin BB & Fallon JF 1995 Changes in the expression of fibroblast growth factor receptors mark distinct stages of chondrogenesis in vitro and during chick limb skeletal patterning. Developmental Dynamics 204 446-456. (doi:10.1002/aja.1002040410)
217. Tanaka E, Ishino Y, Sasaki A, Hasegawa T, Watanabe M, Dalla-Bona DA, Yamano E, van Eijden TM & Tanne K 2006 Fibroblast growth factor-2 augments recombinant human bone morphogenetic protein-2-induced osteoinductive activity. Annals of Biomedical Engineering 34 717-725. (doi:10.1007/s10439-006-9092-x)
218. Tanimoto Y, Yokozeki M, Hiura K, Matsumoto K, Nakanishi H, Matsumoto T, Marie PJ & Moriyama K 2004 A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome. Journal of Biological Chemistry 279 45926-45934. (doi:10.1074/jbc.M404824200)
219. Tavormina PL, Shiang R, Thompson LM, Zhu YZ, Wilkin DJ, Lachman RS, Wilcox WR, Rimoin DL, Cohn DH & Wasmuth JJ 1995 Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nature Genetics 9 321-328. (doi:10.1038/ng0395-321)
220. Toydemir RM, Brassington AE, Bayrak-Toydemir P, Krakowiak PA, Jorde LB, Whitby FG, Longo N, Viskochil DH, Carey JC & Bamshad MJ 2006 A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome. American Journal of Human Genetics 79935-941. (doi:10.1086/508433)
221. Trebicz-Geffen M, Nevo Z, Evron Z, Posternak N, Glaser T, Fridkin M, Kollander Y & Robinson D 2003 The short-lived exostosis induced surgically versus the lasting genetic hereditary multiple exostoses. Experimental and Molecular Pathology 74 40-48. (doi:10.1016/S0014-4800(03)80007-2)
222. Trudel S, Stewart AK, Rom E, Wei E, Li ZH, Kotzer S, Chumakov I, Singer Y, Chang H, Liang SB et al. 2006 The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 107 4039-4046. (doi:10.1182/blood-2005-10-4179)
223. Turnquist J, Ornoy A, Eini D & Schwartz Z 1992 Effects of 1 a(OH)-vitamin D3 and 24,25(OH)2-vitamin D3 on long bones of glucocorticoid-treated rats. Acta Anatomica 145 61-67. (doi:10.1159/000147343)
224. Twigg SR, Healy C, Babbs C, Sharpe JA, Wood WG, Sharpe PT, Morriss-Kay GM & Wilkie AO 2009 Skeletal analysis of the Fgfr3P244R mouse, a genetic model for the Muenke craniosynostosis syndrome. Developmental Dynamics 238 331-342. (doi:10.1002/dvdy.21790)
225. Uchii M, Tamura T, Suda T, Kakuni M, Tanaka A & Miki I 2008 Role of fibroblast growth factor 8 (FGF8) in animal models of osteoarthritis. Arthritis Research & Therapy 10 R90. (doi:10.1186/ar2474)
226. Ueda K, Yamanaka Y, Harada D, Yamagami E, Tanaka H & Seino Y 2007 PTH has the potential to rescue disturbed bone growth in achondroplasia. Bone 41 13-18. (doi:10.1016/j.bone.2007.02.028)
227. Ueno H, Huang X, Tanaka Y & Hirokawa N 2011 KIF16B/Rab14 molecular motor complex is critical for early embryonic development by transporting FGF receptor. Developmental Cell 20 60-71. (doi:10.1016/j. devcel.2010.11.008)
228. Valta MP, Hentunen T, Qu Q, Valve EM, Harjula A, Seppanen JA, Vaananen HK & Harkonen PL 2006 Regulation of osteoblast differentiation: a novel function for fibroblast growth factor 8. Endocrinology 147 2171-2182. (doi:10.1210/en.2005-1502)
229. Valverde-Franco G, Liu H, Davidson D, Chai S, Valderrama-Carvajal H, Goltzman D, Ornitz DM & Henderson JE 2004 Defective bone mineralization and osteopenia in young adult FGFR3K/K mice. Human Molecular Genetics 13 271-284. (doi:10.1093/hmg/ddh034)
230. Valverde-Franco G, Binette JS, Li W, Wang H, Chai S, Laflamme F, Tran-Khanh N, Quenneville E, Meijers T, Poole AR et al. 2006 Defects in articular cartilage metabolism and early arthritis in fibroblast growth FGF signaling on growth plate factor receptor 3 deficient mice. Human Molecular Genetics 15 1783-1792. (doi:10.1093/hmg/ddl100)
231. Verheyden JM & Sun X 2008 An Fgf/Gremlin inhibitory feedback loop triggers termination of limb bud outgrowth. Nature 454 638-641. (doi:10.1038/nature07085)
232. Vidrich A, Buzan JM, Brodrick B, Ilo C, Bradley L, Fendig KS, Sturgill T & Cohn SM 2009 Fibroblast growth factor receptor-3 regulates Paneth cell lineage allocation and accrual of epithelial stem cells during murine intestinal development. American Journal of Physiology. Gastrointestinal and Liver Physiology 297 G168-G178. (doi:10.1152/ajpgi.90589.2008)
233. Wang Y, Spatz MK, Kannan K, Hayk H, Avivi A, Gorivodsky M, Pines M, Yayon A, Lonai P & Givol D 1999 A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3. PNAS 96 4455-4460. (doi:10.1073/pnas.96.8.4455)
234. Wang JM, Du XL, Li CL, Yin LJ, Chen B, Sun J, Su N, Zhao L, Song RH, Song WW et al. 2004 Gly374Arg mutation in Fgfr3 causes achon-droplasia in mice. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 21 537-541.
235. Wang Y, Xiao R, Yang F, Karim BO, Iacovelli AJ, Cai J, Lerner CP, Richtsmeier JT, Leszl JM, Hill CA et al. 2005 Abnormalities in cartilage and bone development in the Apert syndrome FGFR2C/S252W mouse. Development 132 3537-3548. (doi:10.1242/dev.01914)
236. Wang Y, Zhou X, Oberoi K, Phelps R, Couwenhoven R, Sun M, Rezza A, Holmes G, Percival CJ, Friedenthal J et al. 2012 p38 Inhibition ameliorates skin and skull abnormalities in Fgfr2 Beare-Stevenson mice. Journal of Clinical Investigation 122 2153-2164. (doi:10.1172/JCI62644)
237. Weinstein M, Xu X, Ohyama K & Deng CX 1998 FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung. Development 125 3615-3623.
238. Weng T, Yi L, Huang J, Luo F, Wen X, Du X, Chen Q, Deng C, Chen D & Chen L 2012 Genetic inhibition of fibroblast growth factor receptor 1 in knee cartilage attenuates the degeneration of articular cartilage in adult mice. Arthritis and Rheumatism 64 3982-3992. (doi:10.1002/art.34645)
239. White KE, Evans WE, O'Riordan JLH, Speer MC, Econs MJ, Lorenz-Depiereux B, Grabowski M, Meitinger T & Strom TM 2000 Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nature Genetics 26 345-348. (doi:10.1038/81664)
240. White KE, Cabral JM, Davis SI, Fishburn T, Evans WE, Ichikawa S, Fields J, Yu X, Shaw NJ, McLellan NJ et al. 2005 Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. American Journal of Human Genetics 76 361-367. (doi:10.1086/427956)
241. Whitehead CC, McCormack HA, McTeir L & Fleming RH 2004 High vitamin D3 requirements in broilers for bone quality and prevention of tibial dyschondroplasia and interactions with dietary calcium, available phosphorus and vitamin A. British Poultry Science 45 425-436. (doi:10.1080/00071660410001730941)
242. Wilkes D, Rutland P, Pulleyn LJ, Reardon W, Moss C, Ellis JP, Winter RM & Malcolm S 1996 A recurrent mutation, ala391glu, in the trans-membrane region of FGFR3 causes Crouzon syndrome and acanthosis nigricans. Journal of Medical Genetics 33 744-748. (doi:10.1136/jmg.33.9.744)
243. Wilkie AO 2005 Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations. Cytokine & Growth Factor Reviews 16 187-203. (doi:10.1016/j.cytogfr.2005.03.001)
244. Wilkinson CC, Manchester DK, Keating RF, Ketch LL & Winston KR 2012 Syndromic craniosynostosis, fibroblast growth factor receptor 2 (FGFR2) mutations, and sacrococcygeal eversion presenting as human tails. Child's Nervous System 28 1221-1226. (doi:10.1007/s00381-012- 1813-x)
245. Wohrle S, Bonny O, Beluch N, Gaulis S, Stamm C, Scheibler M, Muller M, Kinzel B, Thuery A, Brueggen J et al. 2011 FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. Journal of Bone and Mineral Research 26 2486-2497. (doi:10.1002/jbmr.478)
246. Wohrle S, Henninger C, Bonny O, Thuery A, Beluch N, Hynes NE, Guagnano V, Sellers WR, Hofmann F, Kneissel M et al. 2013 Thematic Review Y XIE and others Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. Journal of Bone and Mineral Research 28 899-911. (doi:10.1002/jbmr.1810)
247. Wu XL, Gu MM, Huang L, Liu XS, Zhang HX, Ding XY, Xu JQ, Cui B, Wang L, Lu SY et al. 2009 Multiple synostoses syndrome is due to a missense mutation in exon 2 of FGF9 gene. American Journal of Human Genetics 85 53-63. (doi:10.1016/j.ajhg.2009.06.007)
248. Wu S, Levenson A, Kharitonenkov A & De Luca F 2012 Fibroblast growth factor 21 (FGF21) inhibits chondrocyte function and growth hormone action directly at the growth plate. Journal of Biological Chemistry 287 26060-26067. (doi:10.1074/jbc.M112.343707)
249. Wuelling M & Vortkamp A 2010 Transcriptional networks controlling chondrocyte proliferation and differentiation during endochondral ossification. Pediatric Nephrology 25 625-631. (doi:10.1007/s00467-009- 1368-6)
250. Xiao L, Naganawa T, Obugunde E, Gronowicz G, Ornitz DM, Coffin JD & Hurley MM 2004 Stat1 controls postnatal bone formation by regulating fibroblast growth factor signaling in osteoblasts. Journal of Biological Chemistry 279 27743-27752. (doi:10.1074/jbc.M314323200)
251. Xiao L, Liu P, Li X, Doetschman T, Coffin JD, Drissi H & Hurley MM 2009 Exported 18-kDa isoform of fibroblast growth factor-2 is a critical determinant of bone mass in mice. Journal of Biological Chemistry 284 3170-3182. (doi:10.1074/jbc.M804900200)
252. Xiao L, Naganawa T, Lorenzo J, Carpenter TO, Coffin JD & Hurley MM 2010 Nuclear isoforms of fibroblast growth factor 2 are novel inducers of hypophosphatemia via modulation of FGF23 and KLOTHO. Journal of Biological Chemistry 285 2834-2846. (doi:10.1074/jbc.M109.030577)
253. Xiao L, Esliger A & Hurley MM 2013 Nuclear fibroblast growth factor 2 (FGF2) isoforms inhibit bone marrow stromal cell mineralization through FGF23/FGFR/MAPK in vitro. Journal of Bone and Mineral Research 2835-45. (doi:10.1002/jbmr.1721)
254. Xie Y, Su N, Jin M, Qi H, Yang J, Li C, Du X, Luo F, Chen B, Shen Y et al. 2012 Intermittent PTH (1-34) injection rescues the retarded skeletal development and postnatal lethality of mice mimicking human achondroplasia and thanatophoric dysplasia. Human Molecular Genetics 213941-3955. (doi:10.1093/hmg/dds181)
255. Xu X, Weinstein M, Li C, Naski M, Cohen RI, Ornitz DM, Leder P & Deng C 1998 Fibroblast growth factor receptor 2 (FGFR2)-mediated reciprocal regulation loop between FGF8 and FGF10 is essential for limb induction. Development 125 753-765.
256. Yamaguchi TP, Harpal K, Henkemeyer M & Rossant J 1994 fgfr-1 is required for embryonic growth and mesodermal patterning during mouse gastrulation. Genes and Development 8 3032-3044. (doi:10.1101/gad.8.24.3032)
257. Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, Yamaguchi K, Yamada Y, Hanada S, Tamura K et al. 2010 Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, FGF signaling on growth plate in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. Journal of Clinical Oncology 28 1591-1598. (doi:10.1200/JCO.2009.25.3575)
258. Yamanaka Y, Tanaka H, Koike M, Nishimura R & Seino Y 2003 PTHrP rescues ATDC5 cells from apoptosis induced by FGF receptor 3 mutation. Journal of Bone and Mineral Research 18 1395-1403. (doi:10.1359/jbmr.2003.18.8.1395)
259. Yang X, Harkins LK, Zubanova O, Harrington A, Kovalenko D, Nadeau RJ, Chen PY, Toher JL, Lindner V, Liaw L et al. 2008 Overexpression of Spry1 in chondrocytes causes attenuated FGFR ubiquitination and sustained ERK activation resulting in chondrodysplasia. Developmental Biology 321 64-76. (doi:10.1016/j.ydbio.2008.05.555)
260. Yano F, Saito T, Ogata N, Yamazawa T, Iino M, Chung UI & Kawaguchi H 2013 b-catenin regulates parathyroid hormone/parathyroid hormone-related protein receptor signals and chondrocyte hypertrophy through binding to the intracellular C-terminal region of the receptor. Arthritis and Rheumatism 65 429-435. (doi:10.1002/art.37779)
261. Yasoda A & Nakao K 2010 Translational research of C-type natriuretic peptide (CNP) into skeletal dysplasias. Endocrine Journal 57 659-666. (doi:10.1507/endocrj.K10E-164)
262. Yin L, Du X, Li C, Xu X, Chen Z, Su N, Zhao L, Qi H, Li F, Xue J et al. 2008 Pro253Arg mutation in fibroblast growth factor receptor 2 (Fgfr2) causes skeleton malformation mimicking human Apert syndrome by affecting both chondrogenesis and osteogenesis. Bone 42 631-643. (doi:10.1016/j.bone.2007.11.019)
263. Yoshiko Y, Wang H, Minamizaki T, Ijuin C, Yamamoto R, Suemune S, Kozai K, Tanne K, Aubin JE & Maeda N 2007 Mineralized tissue cells are a principal source of FGF23. Bone 40 1565-1573. (doi:10.1016/j.bone.2007.01.017)
264. Yu X & White KE 2005 FGF23 and disorders of phosphate homeostasis. Cytokine & Growth Factor Reviews 16 221-232. (doi:10.1016/j.cytogfr.2005.01.002)
265. Yu K & Ornitz DM 2008 FGF signaling regulates mesenchymal differen- tiation and skeletal patterning along the limb bud proximodistal axis. Development 135 483-491. (doi:10.1242/dev.013268)
266. Yu K, Xu J, Liu Z, Sosic D, Shao J, Olson EN, Towler DA & Ornitz DM 2003 Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth. Development 130 3063-3074. (doi:10.1242/dev.00491)
267. Yu X, Ibrahimi OA, Goetz R, Zhang F, Davis SI, Garringer HJ, Linhardt RJ, Ornitz DM, Mohammadi M & White KE 2005 Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 146 4647-4656. (doi:10.1210/en.2005-0670)
268. Zhou YX, Xu X, Chen L, Li C, Brodie SG & Deng CX 2000 A Pro250Arg substitution in mouse Fgfr1 causes increased expression of Cbfa1 and premature fusion of calvarial sutures. Human Molecular Genetics 9 2001-2008. (doi:10.1093/hmg/9.13.2001)